{
    "key_points": [
        "The NIH has started a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of mixed booster COVID-19 vaccine regimens.",
        "The trial is led and funded by the NIAID, part of the NIH, through the Infectious Diseases Clinical Research Consortium.",
        "Anthony S. Fauci, NIAID Director, highlighted the preparation for possible booster shots due to waning immunity and virus evolution.",
        "150 participants who received one of the three FDA Emergency Use Authorized vaccines will receive a booster dose of the Moderna vaccine.",
        "The trial includes separate cohorts for individuals initially unvaccinated, who will then receive the two-dose Moderna vaccine regimen.",
        "An adaptive design of the trial may introduce new arms as additional vaccines receive EUA or variant vaccines are available.",
        "Participants will be followed for a year post-vaccination for safety monitoring, side effects, and immune response evaluations.",
        "The trial seeks to inform public health policy on using mixed vaccine schedules if booster doses become necessary.",
        "Initial results are expected in late summer 2021, with trial information available on clinicaltrials.gov under identifier NCT04889209.",
        "The NIH is the primary federal agency for medical research in the U.S., focusing on infectious, immune-mediated diseases and other illnesses."
    ],
    "spokespersons": [
        "Anthony S. Fauci (Director, NIAID)",
        "Robert L. Atmar, M.D. (Principal Investigator, Baylor College of Medicine)",
        "Kirsten E. Lyke, M.D. (Principal Investigator, University of Maryland, College Park)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}